COMPARE · Data as of August 27, 2026
DHR vs RMD
Verdict: Side-by-side breakdown using the Bull Rankings model. DHR scored 53.8, RMD scored 81.0 — RMD leads.
Compare another set
DHR
Danaher Corporation
53.8
$215.68 · $151.6B
fundamentals as of
Score gap
27.2
RMD leads
RMD
ResMed Inc.
81
$236.49 · $34.1B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestRMD22.7x
- Fastest growthRMD+9.9%
- Strongest balance sheetRMD0.13
- Highest qualityRMD90 / 100
- Largest discount to fair valueRMD-2%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
DHR
stronger →← stronger
RMD
62
Qualityreturns · margins · balance sheet
90
60
Growthrevenue & earnings expansion
82
42
Valuevaluation vs sector peers
72
RMD is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
DHR
RMD
$5.5bB+
FCF
$1.6bC+
+4.6%C+
Rev
+9.9%B
0.53B
D/E
0.13B+
38.5xC+
P/E
22.7xB+
1.41B
PEG
1.34B
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
DHR
RMD
37% above
Price vs fair valuelower is cheaper
2% below
~14%/yr
Growth the price implies10-yr FCF · lower = less priced in
~6%/yr
-33%
1-yr DCF upside
-6%
-27%
5-yr DCF upside
+2%
-18%
10-yr DCF upside
+16%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
DHR
Why this score
- Raising its dividend
RMD
Why this score
- Raising its dividend
- Durable high returns
The companies
DHRDanaher Corporation
Why now
Diagnostics & Research · market cap $151.6b. 11% off the 52-week high of $242.80. 23 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $227.96 (implying +6% upside).
Moat
Net margin 16% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. FCF converts 137% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. $151.6b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Trailing P/E 39x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. ROE 8% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
RMDResMed Inc.
Why now
Medical Instruments & Supplies · market cap $34.1b. 17% off the 52-week high of $284.87. 16 sell-side analysts rate this a Buy with a mean 1-yr target of $245.50 (implying +4% upside).
Moat
Net margin 27% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 23% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 108% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where DHR and RMD diverge
On the headline score the gap is 27.2 points in favor of RMD. The widest single difference is Value, where RMD leads by 30.4 points.
- ValueDHR 41.7 · RMD 72.1RMD +30.4
- QualityDHR 62.0 · RMD 90.3RMD +28.3
- GrowthDHR 60.4 · RMD 81.6RMD +21.2
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.